Banook Group (FR) acquired B.Research (AU), expanding its portfolio in electronic Clinical Outcome Assessment (eCOA) technology for clinical trials.
| Acquirer | Banook Group (FR) |
| Target | B.Research (AU) |
| Deal Value | Undisclosed |
| Stake Acquired | 100% |
| Type | Acquisition |
| Closing Date | 2024-06-11 |
| Announcement Date | 2023-11-01 |
| Buy-Side Advisors | Houlihan Lokey, Baker & McKenzie (legal) |
Banook Group, a provider of technology and services for clinical trial operators, acquired B.Research to bolster its eCOA capabilities. The deal enables Banook to offer comprehensive imaging and eCOA solutions, solidifying its position as a leader in European service technologies for clinical trials.
Deal Mechanics
Banook Group completed the acquisition of B.Research on June 11, 2024. The transaction was advised by Houlihan Lokey and Baker & McKenzie (legal) on behalf of Banook Group. Financial terms were not disclosed.
Strategic Rationale
The acquisition of B.Research allows Banook Group to extend its service offerings across the clinical trial value chain, particularly in eCOA. This move complements Banook's existing expertise in cardiac safety and imaging services, enhancing its competitive edge in the European market.
With this acquisition, Banook Group aims to accelerate its international expansion, especially into North America, by leveraging B.Research’s strong presence in Australia and its platform's capabilities for digital data capture from patients. This strategic addition supports Banook's ambition to become a global leader in technology services for clinical trials.
Financial Context
Banook Group, founded in 1999 in Nancy, France, has been supported by Motion Equity Partners since November 2023 to enhance its external growth strategy. The company now employs nearly 120 staff distributed across Europe, North America, and the Asia-Pacific region.
Outlook
Banook Group expects this acquisition to drive further international development, particularly in the United States, as it seeks to expand its service offerings to better meet client demands. The group anticipates continued growth through diversification of services and skillsets to remain at the forefront of the clinical trial technology market.